Canada approves new obesity drug to reduce risk of non-fatal heart attack
- GLP-1 receptor agonists reduced the risk of kidney failure by 16% and worsening kidney function by 22%, according to a comprehensive analysis.
- The analysis also showed a 14% reduction in cardiovascular death and events with GLP-1 receptor agonists compared to placebo.
- Additionally, there was a 13% lower risk of death from any cause among patients treated with GLP-1 receptor agonists.
Insights by Ground AI
Does this summary seem wrong?
Coverage Details
Total News Sources0
Leaning Left6Leaning Right0Center6Last UpdatedBias Distribution50% Left, 50% Center
Bias Distribution
- 50% of the sources lean Left, 50% of the sources are Center
50% Center
L 50%
C 50%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
